Filing Flows › Gossamer Bio (GOSS) › Q1 2025
Gossamer Bio (GOSS) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 15, 2025
Gossamer Bio (GOSS) reported revenue of $9.9M for the first quarter 2025 (Q1 2025) and +5% from the quarter before. Operating margin was -372.2%, net loss $36.6M (370.5% of revenue).
Gossamer Bio, Q1 2025: revenue $9.9M, operating margin -372.2%, net loss $36.6M, operating cash flow −$39.7M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.9M | +5% | — |
| Operating profit | −$36.8M | — | — |
| Net earnings | −$36.6M | — | — |
| Operating cash flow | −$39.7M | — | — |
What changed
Revenue was $9.9M in Q1 2025, up 5% from the previous quarter.
Operating costs exceeded revenue by $36.8M, an operating margin of -372.2%. The quarter ended with a net loss of $36.6M, wider than the previous quarter's $33.0M loss.
Operating cash flow was −$39.7M. Non-cash charges added back $6K of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $5.5M. Capital expenditures of $26K exceeded it, leaving free cash flow of −$39.8M.
Questions
What was Gossamer Bio's revenue in the first quarter 2025?
Gossamer Bio (GOSS) reported revenue of $9.9M for the first quarter 2025 (Q1 2025) and +5% from the quarter before.
Was Gossamer Bio profitable in the first quarter 2025?
Operating loss was $36.8M (-372.2% of revenue) and net loss $36.6M.
Source: Gossamer Bio 10-Q on SEC EDGAR.